Pyridoxamine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pyridoxamine" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

7doi.org

2^nd place

7web.archive.org

1^st place

4semanticscholar.org

11^th place

8^th place

2regulations.gov

low place

1qmul.ac.uk

1,735^th place

3,129^th place

1harvard.edu

18^th place

17^th place

1biomedcentral.com

2,747^th place

7,129^th place

1newsfood.com

low place

1bizjournals.com

407^th place

241^st place

1entrepreneur.com

2,631^st place

1,557^th place

1renalbusiness.com

low place

1nephrogenex.com

low place

1fdanews.com

low place

biomedcentral.com

Giannoukakis N (2005). "Pyridoxamine (BioStratum)" (PDF). Curr Opin Investig Drugs. 6 (4): 410–8. PMID 15898348.^{[permanent dead link‍]}

bizjournals.com

triangle.bizjournals.com

"Big problem for BioStratum" Archived 2016-08-13 at the Wayback Machine, Triangle Business Journal, October 14, 2005

doi.org

Adrover M, Vilanova B, Frau J, Muñoz F, Donoso J (May 2008). "The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect". Bioorg. Med. Chem. 16 (10): 5557–69. doi:10.1016/j.bmc.2008.04.002. PMID 18434162.
Voziyan PA, Hudson BG (2005). "Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage". Cell. Mol. Life Sci. 62 (15): 1671–81. doi:10.1007/s00018-005-5082-7. PMC 11139091. PMID 15905958. S2CID 42229880.
Voziyan PA, Hudson BG (2005). "Pyridoxamine: the many virtues of a maillard reaction inhibitor". Ann. N. Y. Acad. Sci. 1043 (1): 807–16. Bibcode:2005NYASA1043..807V. doi:10.1196/annals.1333.093. PMID 16037308. S2CID 23569767.
Ahmed N, Thornalley PJ (2007). "Advanced glycation endproducts: what is their relevance to diabetic complications?". Diabetes Obes Metab. 9 (3): 233–45. doi:10.1111/j.1463-1326.2006.00595.x. PMID 17391149. S2CID 25368439.
Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB (2007). "Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy". Am. J. Nephrol. 27 (6): 605–14. doi:10.1159/000108104. PMID 17823506. S2CID 6057909.
Metz TO, Alderson NL, Thorpe SR, Baynes JW (2003). "Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications". Arch. Biochem. Biophys. 419 (1): 41–9. doi:10.1016/j.abb.2003.08.021. PMID 14568007.
Thotala D, Chetyrkin S, Hudson B, Hallahan D, Voziyan P, Yazlovitskaya E (September 2009). "Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis". Free Radic. Biol. Med. 47 (6): 779–85. doi:10.1016/j.freeradbiomed.2009.06.020. PMC 2739572. PMID 19540915.

entrepreneur.com

"FDA's pyridoxamine decision: FDA's decision regarding pyridoxamine has larger implications for dietary ingredients in general", Entrepreneur, April, 2009

fdanews.com

"Citizen Petition" (PDF). fdanews.com. 2017-10-23. Archived (PDF) from the original on 2023-11-10. Retrieved 2023-11-10.

harvard.edu

ui.adsabs.harvard.edu

Voziyan PA, Hudson BG (2005). "Pyridoxamine: the many virtues of a maillard reaction inhibitor". Ann. N. Y. Acad. Sci. 1043 (1): 807–16. Bibcode:2005NYASA1043..807V. doi:10.1196/annals.1333.093. PMID 16037308. S2CID 23569767.

nephrogenex.com

"NephroGenex - Innovative Therapies for Kidney Disease - News". Archived from the original on 2012-01-25. Retrieved 2012-03-08.

newsfood.com

"FDA finds vitamin B6 form not legal in supplements" Archived 2022-09-26 at the Wayback Machine, newsfood.com, February 2, 2009

nih.gov

pubmed.ncbi.nlm.nih.gov

Adrover M, Vilanova B, Frau J, Muñoz F, Donoso J (May 2008). "The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect". Bioorg. Med. Chem. 16 (10): 5557–69. doi:10.1016/j.bmc.2008.04.002. PMID 18434162.
Voziyan PA, Hudson BG (2005). "Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage". Cell. Mol. Life Sci. 62 (15): 1671–81. doi:10.1007/s00018-005-5082-7. PMC 11139091. PMID 15905958. S2CID 42229880.
Voziyan PA, Hudson BG (2005). "Pyridoxamine: the many virtues of a maillard reaction inhibitor". Ann. N. Y. Acad. Sci. 1043 (1): 807–16. Bibcode:2005NYASA1043..807V. doi:10.1196/annals.1333.093. PMID 16037308. S2CID 23569767.
Ahmed N, Thornalley PJ (2007). "Advanced glycation endproducts: what is their relevance to diabetic complications?". Diabetes Obes Metab. 9 (3): 233–45. doi:10.1111/j.1463-1326.2006.00595.x. PMID 17391149. S2CID 25368439.
Giannoukakis N (2005). "Pyridoxamine (BioStratum)" (PDF). Curr Opin Investig Drugs. 6 (4): 410–8. PMID 15898348.^{[permanent dead link‍]}
Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB (2007). "Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy". Am. J. Nephrol. 27 (6): 605–14. doi:10.1159/000108104. PMID 17823506. S2CID 6057909.
Metz TO, Alderson NL, Thorpe SR, Baynes JW (2003). "Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications". Arch. Biochem. Biophys. 419 (1): 41–9. doi:10.1016/j.abb.2003.08.021. PMID 14568007.
Thotala D, Chetyrkin S, Hudson B, Hallahan D, Voziyan P, Yazlovitskaya E (September 2009). "Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis". Free Radic. Biol. Med. 47 (6): 779–85. doi:10.1016/j.freeradbiomed.2009.06.020. PMC 2739572. PMID 19540915.

ncbi.nlm.nih.gov

Voziyan PA, Hudson BG (2005). "Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage". Cell. Mol. Life Sci. 62 (15): 1671–81. doi:10.1007/s00018-005-5082-7. PMC 11139091. PMID 15905958. S2CID 42229880.
Thotala D, Chetyrkin S, Hudson B, Hallahan D, Voziyan P, Yazlovitskaya E (September 2009). "Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis". Free Radic. Biol. Med. 47 (6): 779–85. doi:10.1016/j.freeradbiomed.2009.06.020. PMC 2739572. PMID 19540915.

qmul.ac.uk

iupac.qmul.ac.uk

"Vitamin B-6". iupac.qmul.ac.uk. Retrieved 2024-09-26.

regulations.gov

"Regulations.gov". Archived from the original on 2012-09-25. Retrieved 2011-10-23.
FDA-2005-P-0259-0004 Archived 2012-09-25 at the Wayback Machine: FDA Response to Biostratum, Inc. (Kathleen M Sanzo, Esq) - Petition Partial Approved and Denial

renalbusiness.com

"NephroGenex acquires rights to diabetic nephropathy drug". www.renalbusiness.com. Archived from the original on 2010-12-31.

semanticscholar.org

api.semanticscholar.org

Voziyan PA, Hudson BG (2005). "Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage". Cell. Mol. Life Sci. 62 (15): 1671–81. doi:10.1007/s00018-005-5082-7. PMC 11139091. PMID 15905958. S2CID 42229880.
Voziyan PA, Hudson BG (2005). "Pyridoxamine: the many virtues of a maillard reaction inhibitor". Ann. N. Y. Acad. Sci. 1043 (1): 807–16. Bibcode:2005NYASA1043..807V. doi:10.1196/annals.1333.093. PMID 16037308. S2CID 23569767.
Ahmed N, Thornalley PJ (2007). "Advanced glycation endproducts: what is their relevance to diabetic complications?". Diabetes Obes Metab. 9 (3): 233–45. doi:10.1111/j.1463-1326.2006.00595.x. PMID 17391149. S2CID 25368439.
Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB (2007). "Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy". Am. J. Nephrol. 27 (6): 605–14. doi:10.1159/000108104. PMID 17823506. S2CID 6057909.

web.archive.org

"FDA finds vitamin B6 form not legal in supplements" Archived 2022-09-26 at the Wayback Machine, newsfood.com, February 2, 2009
"Big problem for BioStratum" Archived 2016-08-13 at the Wayback Machine, Triangle Business Journal, October 14, 2005
"Regulations.gov". Archived from the original on 2012-09-25. Retrieved 2011-10-23.
FDA-2005-P-0259-0004 Archived 2012-09-25 at the Wayback Machine: FDA Response to Biostratum, Inc. (Kathleen M Sanzo, Esq) - Petition Partial Approved and Denial
"NephroGenex acquires rights to diabetic nephropathy drug". www.renalbusiness.com. Archived from the original on 2010-12-31.
"NephroGenex - Innovative Therapies for Kidney Disease - News". Archived from the original on 2012-01-25. Retrieved 2012-03-08.
"Citizen Petition" (PDF). fdanews.com. 2017-10-23. Archived (PDF) from the original on 2023-11-10. Retrieved 2023-11-10.